Nasal Cavity and Paranasal Sinus Tumors: A Multi-Disciplinary Discussion

The management of patients with nasal cavity and paranasal sinus tumors is challenging and constantly evolving. It often requires true trimodality care involving radiation oncology, otolaryngology and medical oncology, along with a variety of different supportive services. These tumors are challenging to treat even for high-volume providers specializing in head and neck cancer as they often place providers at the edge of the therapeutic window of surgery and radiation. We discuss the most recent advances in the field from a multi-disciplinary setting including a radiation oncologist, medical oncologist and skull base surgeon to inform the audience of the most critical recent updates in the field to optimize the management of this challenging-to-treat patient population. 

Topics:

  1. Neoadjuvant Therapy in Nasal Cavity/Paranasal Sinus Tumors
    Nabil F. Saba, MD, FACP
  2. Modern Surgical Management of Nasal Cavity/Paranasal Sinus Tumors 
    Katie Phillips, MD
  3. Advanced Radiation Techniques in the Management of Nasal Cavity/Paranasal Sinus Cancers 
    Adam L. Holtzman, MD
  4. Q and A
    James E. Bates, MD – Moderator
    Full Panel

This activity is available from August 18, 2026, through 11:59 p.m. Eastern time on August 17, 2028. 

The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, residents and ENT's.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the role of neoadjuvant chemotherapy in patients with nasal cavity/paranasal sinus tumors.
  • Explain the value of advanced radiation techniques in the treatment of patients with nasal cavity/paranasal sinus tumors.
  • Discuss the surgical approaches for and management of nasal cavity/paranasal sinus tumors and how that may impact subsequent adjuvant treatment.

Course summary

Available credit: 
  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
08/18/2026
Course expires: 
08/17/2028
Cost:
$149.00
Rating: 
0

Moderator:  

  • James E. Bates, MD, is employed by Emory University Hospital Midtown. Dr. Bates has no relevant financial relationship with ineligible companies to disclose.

Speakers:

  • Nabil F. Saba, MD, FACP, is employed by Emory University. Dr. Saba receives grant/research funding and honoraria from AstraZeneca, Exelixis, BionTech and TOSK. Dr. Saba receives travel expenses and honoraria from MedScape, Onclive, Springer and UpToDate.   
  • Katie Phillips, MD, is employed by University of Cincinnati. Dr. Phillips owns stock options with Sound Health.  
  • Adam L. Holtzman, MD, is employed by Mayo Clinic – Florida. Dr. Holtzman has no relevant financial relationship with ineligible companies to disclose.  

Planners:

  • Malcolm Mattes, MD, is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies. 
  • Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies. 
  • Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
  • Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems. 
  • Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical. 
     

All relevant financial relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

  • Nonmember: $149
  • Member: $99
  • Member-in-Training: $49
  • Student/Graduate Student/PGY-1 Member: $49
  • Postdoctoral Fellow Member: $49

If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date. 

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until August 17, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date. 

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.